Clinical experiences with 6-monthly paliperidone palmitate after 12 months of use. A retrospective study

Clinical experiences with 6-monthly paliperidone palmitate after 12 months of use. A retrospective study

Introduction Long-acting injectable antipsychotics (LAIA) have provided a significant improvement in the treatment of schizophrenia. Although there is already significant clinical experience with paliperidone palmitate, it is important to evaluate the clinical response of patients to this new 6-mon...

Full description

Bibliographic Details
Main Authors:	S. Benavente López, A. Parra González, S. Bolaño Mendoza, A. Lara Fernández, A. Herencias Nevado, E. Baca García
Format:	Article
Language:	English
Published:	Cambridge University Press 2023-03-01
Series:	European Psychiatry
Online Access:	https://www.cambridge.org/core/product/identifier/S092493382301043X/type/journal_article

Similar Items

Alternative initiations with 6-monthly paliperidone palmitate. A retrospective study
by: S. Benavente López, et al.
Published: (2023-03-01)

Clinical experiences with 6-monthly paliperidone palmitate beyond the diagnosis of schizophrenia. A retrospective study
by: S. Benavente López, et al.
Published: (2023-03-01)

Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
by: P. Escobedo-Aedo, et al.
Published: (2022-06-01)

Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
by: Ibrahim Turkoz, et al.
Published: (2023-09-01)

PALIPERIDONE PALMITATE 6-MONTH FORMULATION FOR THE TREATMENT OF SCHIZOPHRENIA: A 4-MONTH FOLLOW-UP STUDY
by: S. L. Romero Guillena, et al.
Published: (2023-03-01)

Predictors of transition from paliperidone palmitate 1 and 3 months (PP1M & PPP3M) to paliperidone palmitate 6 months (PP6M)
by: P. J. Escobedo-Aedo, et al.
Published: (2023-03-01)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
by: Olivier Corbeil, et al.
Published: (2022-11-01)

Alternative initiations with 6-monthly paliperidone palmitate. A descriptive study
by: O. C. Sobrino, et al.
Published: (2023-03-01)

Retrospective analysis of hospitalization rates in patients with schizophrenia 12 months before and 12 months after the switch on once-monthly long-acting injectable paliperidone palmitate
by: Totić-Poznanović Sanja, et al.
Published: (2023-01-01)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
by: Mathews M, et al.
Published: (2019-05-01)

Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia
by: Juan J. Fernández-Miranda, et al.
Published: (2021-04-01)

Relapse and frequency of injection of monthly paliperidone palmitate—A retrospective case–control study
by: Emily Laing, et al.
Published: (2021-01-01)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
by: Lopez A, et al.
Published: (2019-02-01)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
by: El Khoury AC, et al.
Published: (2021-10-01)

Efficacy of paliperidone palmitate 3-month formulation in preventing hospital admissions. 60 months of follow-up
by: S.L. Romero Guillena, et al.
Published: (2022-06-01)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
by: O'Donnell A, et al.
Published: (2021-01-01)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
by: Charmi Patel, et al.
Published: (2019-11-01)

Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs
by: Di Lorenzo R, et al.
Published: (2022-04-01)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
by: Nash AI, et al.
Published: (2019-03-01)

A case report of pregnancy and paliperidone palmitate 3‐monthly long‐acting injection
by: Rita deAzevedo Avelar, et al.
Published: (2020-12-01)

Efficacy of paliperidone palmitate 3-month formulation in preventing hospital admissions and emergency room visits. 66 months of follow-up
by: S. L. Romero Guillena, et al.
Published: (2023-03-01)

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
by: Li G, et al.
Published: (2021-10-01)

Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate
by: Rebekka Lencer, et al.
Published: (2021-05-01)

Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study
by: Giron‐Hernandez C, et al.
Published: (2023-04-01)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
by: Sliwa JK, et al.
Published: (2012-08-01)

Preliminary data from a 4-year mirror-image and multicentre study of patients initiating paliperidone palmitate 6-monthly long-acting injectable antipsychotic: the Paliperidone 2 per Year study
by: Juan Antonio García-Carmona, et al.
Published: (2023-12-01)

Alternative initiations of three-monthly and six-monthly paliperidone palmitate in a psychiatric hospitalization unit. About two clinical cases.
by: V. Juárez Calvo, et al.
Published: (2023-03-01)

Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study
by: Miquel Bioque, et al.
Published: (2020-01-01)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
by: Mathews M, et al.
Published: (2018-10-01)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
by: Si T, et al.
Published: (2019-06-01)

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
by: Savitz AJ, et al.
Published: (2019-02-01)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
by: Emsley R, et al.
Published: (2017-08-01)

Clinical relevance of Paliperidone Palmitate three-month intramuscular injection formulation: an Italian Real-World, Retrospective, one-year Mirror Image Study
by: S. Vanzetto, et al.
Published: (2022-06-01)

Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal
by: García-Carmona JA, et al.
Published: (2023-09-01)

Clinical outcomes with paliperidone palmitate 3-monthly injection as monotherapy: observational 3-year follow-up of patients with schizophrenia
by: Ivana Clark, et al.
Published: (2024-01-01)

Patients’ perspectives on switching from one to three monthly Paliperidone Palmitate a cross-sectional patient satisfaction survey
by: J. Barnett, et al.
Published: (2023-03-01)

One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients’, Relatives’, and Mental Health Professionals’ Perspectives
by: Spoelstra SK, et al.
Published: (2022-03-01)

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
by: Christophe Sapin, et al.
Published: (2016-09-01)

Once-monthly paliperidone injection for the treatment of schizophrenia
by: Delia Bishara
Published: (2010-09-01)

Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis
by: Charmi Patel, MPH, RN, et al.
Published: (2020-01-01)